Iceland· IS-EU/1/09/544/001-004
Cimzia
A certolizumab pegol product containing certolizumabum pegolum inn, registered in Iceland by UCB Pharma S.A.*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Certolizumab pegol is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AB05 (certolizumab pegol), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Certolizumab pegol · ATC L04AB05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of certolizumab pegol costs, country by country.
Normalised to the WHO defined daily dose (14 mg), the median price runs from $0.17 in Finland to $41.63 in Switzerland — a ×241 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Certolizumab pegol · price per daily dose (14 mg)
USD · FX 28 Sept 2026
- CH Switzerland$41.63
- FI Finland$0.17
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Certolizumabum pegolum INN
- Manufacturer
- UCB Pharma S.A.*
- Country
- Iceland (IS)
- ATC code
- L04AB05
- ATC class
- Certolizumab pegol
- Defined daily dose
- 14 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean9969521 ml x2 sprISK 187905
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
430 interactions on record for certolizumab pegol.
Graded by severity as the source publishes them — 286 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Certolizumab pegol · interactions on record
430 records
- 286 severe
- 137 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Certolizumab pegol in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCIMZIAUCB Pharma SA, Brusel
- SpainCIMZIA 200 MG SOLUCION INYECTABLE EN CARTUCHO PARA DISPENSADOR DE DOSISUcb Pharma
- BelgiumCimzia 200 mgUCB Pharma
- United KingdomCimzia 200mg/1ml solution for injection in a dose-dispenser cartridgeUCB Pharma Ltd
- SwedenCimzia 200 mg Injektionsvätska, lösning i förfylld injektionspennaUCB Pharma S.A.
- NorwayCimziaUCB Pharma S.A. (2)
- PolandCimziaUCB Pharma S.A.
- FinlandCimziaParanova Oy
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Cimzia
- Norway · Cimzia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a68da9d9-9c3f-45e9-83d8-a7b64952dd34 GET /v1/drugs/a68da9d9-9c3f-45e9-83d8-a7b64952dd34?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stungulyf, lausn í áfylltri sprautu",
"source": "lyfjastofnun",
"atc_raw": "L04AB05",
"marketed": false,
"strength": "200 mg",
"ma_number": "EU/1/09/544/001-004",
"substance": "Certolizumabum pegolum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í gigtarlækningum, húðsjúkdómum og ónæmisfræði.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "40141"
}See everything about certolizumab pegol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.